M3/M3v acute non lymphocytic leukemia (M3-ANLL) - M3/M3v acute myeloid leukemia (AML M3/M3v) - Acute promyelocytic leukemia (APL)

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Acute myeloid leukemia and acute promyelocytic leukemia.

The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel...

متن کامل

The role of microRNA in acute/chronic, myeloid/lymphocytic leukemia

MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...

متن کامل

Acute myeloid leukemia pretreated with filgrastim mimicking acute promyelocytic leukemia.

A 66-year-old man with a history of hepatitis C virus and liver transplantation presented to the emergency department for shortness of breath. He had received weekly filgrastim for chronic neutropenia, and immediately before admission he had received 3 days of filgrastim and 1 day of pegfilgrastim. A hemogram showed a white blood cell count of 4.54 K/mL with 23% blastic cells. Emergent bone mar...

متن کامل

Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia

Background:  Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Atlas of Genetics and Cytogenetics in Oncology and Haematology

سال: 2011

ISSN: 1768-3262

DOI: 10.4267/2042/38325